REST ASSURED -
VETMEDIN can be prescribed with confidence
Safety and administration
VETMEDIN can be prescribed with confidence based on its proven track record of
safety in nearly 10 years of worldwide use.1 More than 300 million doses have been
sold since 1999.1
Rigorous licensing and toxicity studies demonstrated the excellent safety profile of
VETMEDIN.2 In addition, the extensive VetSCOPE3 and QUEST4 clinical trials assure
veterinarians of VETMEDIN safety for use in dogs with congestive heart failure
(CHF).
VETMEDIN also offers convenient, easy administration to help ensure client
compliance and best results in patients. Packaged in 50-count bottles, VETMEDIN
Chewable Tablets are scored and highly palatable. This convenience and ease of
administration helps ensure client and patient compliance for best possible results.
Important safety information
In foreign, post-approval drug experience reporting, the following additional suspected adverse reactions were reported in dogs treated with a capsule formulation of VETMEDIN:
- Hemorrhage
- Petechia
- Anemia
- Hyperactivity
- Excited behavior
- Erythema
- Rash
- Drooling
- Constipation
- Diabetes mellitus
In the QUEST trial, VETMEDIN appeared to be well tolerated with a low number of adverse events. Observed adverse events in both the VETMEDIN (n=18) and ACE inhibitor (n=17) groups were very similar. Gastrointestinal disorders were most common (n=6 and 4, respectively), followed by abnormal behavior, such as lethargy, confusion, or uneasiness (n=3 and 4, respectively). Three dogs treated with VETMEDIN were reported to have had a seizure.
In the VetSCOPE trial, there were 3 adverse events in the VETMEDIN group and 1 in the ACE inhibitor group. Diarrhea, soft stool, and vomiting occurred in the VETMEDIN group (1 dog each) and colitis occurred in the ACE inhibitor group.
References:
1. Data on file, Boehringer Ingelheim Vetmedica, Inc.
2. VETMEDIN® (pimobendan) Chewable Tablets [Freedom of Information Summary]. St.
Joseph, MO: Boehringer Ingelheim Vetmedica, Inc.; 2007.
3. Lombard CW, Jöns O, Bussadori CM; for the VetSCOPE Study. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc. 2006;42(4):249–261.
4. Häggström J, Boswood A, O’Grady M, et al. Effect of pimobendan or benazepril
hydrochloride on survival times in dogs with congestive heart failure caused by naturally
occurring myxomatous mitral valve disease: the QUEST study. J Vet Intern Med.
2008;22(5):1124–1135.